Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Total Non-Current Liabilities: 2022-2023

Historic Total Non-Current Liabilities for Immunocore Holdings (IMCR) over the last 2 years, with Dec 2023 value amounting to $227.2 million.

  • Immunocore Holdings' Total Non-Current Liabilities fell 13.42% to $609.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $609.3 million, marking a year-over-year decrease of 13.42%. This contributed to the annual value of $227.2 million for FY2023, which is 22.37% up from last year.
  • Latest data reveals that Immunocore Holdings reported Total Non-Current Liabilities of $227.2 million as of FY2023, which was up 22.37% from $185.6 million recorded in FY2022.
  • Immunocore Holdings' Total Non-Current Liabilities' 5-year high stood at $227.2 million during FY2023, with a 5-year trough of $185.6 million in FY2022.
  • Its 2-year average for Total Non-Current Liabilities is $206.4 million, with a median of $206.4 million in 2022.
  • Data for Immunocore Holdings' Total Non-Current Liabilities shows a peak YoY grew of 22.37% (in 2023) over the last 5 years.
  • Immunocore Holdings' Total Non-Current Liabilities (Yearly) stood at $185.6 million in 2022, then grew by 22.37% to $227.2 million in 2023.